NILAM BHUSARE, MAUSHMI KUMAR^*

Oncology Research, Vol.32, No.5, pp. 849-875, 2024, DOI:10.32604/or.2024.047042 - 23 April 2024

Abstract Glioblastoma, the most aggressive form of brain tumor, poses significant challenges in terms of treatment success and patient survival. Current treatment modalities for glioblastoma include radiation therapy, surgical intervention, and chemotherapy. Unfortunately, the median survival rate remains dishearteningly low at 12–15 months. One of the major obstacles in treating glioblastoma is the recurrence of tumors, making chemotherapy the primary approach for secondary glioma patients. However, the efficacy of drugs is hampered by the presence of the blood-brain barrier and multidrug resistance mechanisms. Consequently, considerable research efforts have been directed toward understanding the underlying signaling pathways… More > Graphic Abstract

ZHAOHUI HU^1,2, XIANGJUN DING³, YUYAO JI², XIAOHONG LIU^4,*, ZHIWEN DING^2,*

BIOCELL, Vol.45, No.3, pp. 745-749, 2021, DOI:10.32604/biocell.2021.013293 - 03 March 2021

Abstract Apurine/pyrimidine-free endonuclease 1 (APEX1) is a multifunctional enzyme that contributes to oxidizationmediated DNA-cleaved base excision repair and redox activation of transcription factors. However, the role of APEX1 during cardiomyocyte oxidative stress injury is not completely understood. In the present study, whether APEX1 protects oxidative damage-induced cardiomyocytes was investigated. mRNA and protein expression levels of APEX1 were downregulated in the mouse model of cardiac ischemia-reperfusion injury. Furthermore, the expression of APEX1 in hydrogen peroxide (H₂O₂)-treated neonatal mice cardiomyocytes was also decreased. APEX1 knockdown aggravated H₂O₂-treated cardiomyocyte apoptosis indexes. By contrast, APEX1 overexpression reversed H₂O₂-induced oxidative damage, as demonstrated More >

Andrea Lapucci^*†1, Gabriele Perrone^*†1, Antonello Di Paolo^‡§, Cristina Napoli^*†, Ida Landini^*†, Giandomenico Roviello^*†, Laura Calosi^¶, Antonio Giuseppe Naccarato^#, Alfredo Falcone^#, Daniele Bani^¶, Enrico Mini^*†§2, Stefania Nobili^*†§2,3

Oncology Research, Vol.28, No.6, pp. 631-644, 2020, DOI:10.3727/096504020X16056983169118

Abstract The benefit of adjuvant chemotherapy in the early stages of colorectal cancer (CRC) is still disappointing and the prediction of treatment outcome quite difficult. Recently, through a transcriptomic approach, we evidenced a role of PNN and KCNQ1OT1 gene expression in predicting response to fluoropyrimidine-based adjuvant chemotherapy in stage III CRC patients. Thus, the aim of this study was to validate in an independent cohort of stages II–III CRC patients our previous findings. PNN and KCNQ1OT1 mRNA expression levels were evaluated in 74 formalin-fixed paraffin-embedded tumor and matched normal mucosa samples obtained by stages II–III CRC patients treated… More >

Ching-Wen Huang^*, Cheng-Jen Ma^*†, Wei-Chih Su^*, Yi-Ting Chen^‡§, Hsiang-Lin Tsai^*¶, Yung-Sung Yeh^*#, Tsung-Kun Chang^*, Wen-Hung Hsu^**††, Fang-Jung Yu^**††, Jaw-Yuan Wang^{*¶‡‡§§¶¶##}

Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822

Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study… More >